Molecular & Cellular Immunology, Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital Trust, London, UK.
Br J Haematol. 2014 Sep;166(6):818-29. doi: 10.1111/bjh.12981. Epub 2014 Jun 17.
Proof-of-concept studies have demonstrated the therapeutic potential of engineered T cells. Transfer of recombinant antigen-specific T cell receptors (TCR) and chimaeric antigen receptors (CARs) against tumour and viral antigens are under investigation by multiple approaches, including viral- and nonviral-mediated gene transfer into both autologous and allogeneic T cell populations. There have been notable successes recently using viral vector-mediated transfer of CARs specific for B cell antigens, but also reports of anticipated and unanticipated complications in these and other studies. We review progress in this promising area of cellular therapy, and consider developments in antigen receptor therapies including the application of emerging gene-editing technologies.
概念验证研究已经证明了工程化 T 细胞的治疗潜力。通过多种方法正在研究针对肿瘤和病毒抗原的重组抗原特异性 T 细胞受体 (TCR) 和嵌合抗原受体 (CAR) 的转移，包括病毒和非病毒介导的基因转移到自体和同种异体 T 细胞群体中。最近，使用针对 B 细胞抗原的 CAR 病毒载体介导的转移取得了显著的成功，但在这些和其他研究中也有预期和意外并发症的报告。我们回顾了细胞治疗这一有前途的领域的进展，并考虑了抗原受体疗法的发展，包括新兴基因编辑技术的应用。
